Loading…
PDS Biotechnology Corporation is projected to rise to $0.7906 by 2027, a +4% move from its current price of $0.7575. PDSB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.7253 | $0.7574 | $0.791 | -0.01% |
| Jul 14 | $0.7123 | $0.7574 | $0.8053 | -0.02% |
| Jul 15 | $0.7025 | $0.7573 | $0.8164 | -0.03% |
| Jul 16 | $0.6943 | $0.7572 | $0.8259 | -0.03% |
| Jul 17 | $0.6871 | $0.7572 | $0.8344 | -0.04% |
| Jul 18 | $0.6807 | $0.7571 | $0.8421 | -0.05% |
| Jul 19 | $0.6749 | $0.7571 | $0.8492 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6749 | $0.7571 | $0.8492 | -0.06% |
| Week 2 | $0.6432 | $0.7566 | $0.89 | -0.12% |
| Week 3 | $0.6198 | $0.7562 | $0.9226 | -0.18% |
| Week 4 | $0.6006 | $0.7557 | $0.9508 | -0.24% |
| Week 5 | $0.5842 | $0.7553 | $0.9764 | -0.30% |
| Week 6 | $0.5697 | $0.7548 | $1.00 | -0.35% |
| Week 7 | $0.5567 | $0.7544 | $1.02 | -0.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies in the United States. Its lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops PDS0102 for treating acute myeloid leukemia, prostate, and breast cancer, and PDS0103 for ovarian, breast, colorectal, and lung cancers; in addition, the company is developing PDS01ADC, a novel interleukin 12 fused antibody-drug conjugate that targets tumors.
The company has license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology was founded in 2005 and is based in Princeton, New Jersey.
PDS Biotechnology Corporation (PDSB) operates in Healthcare and is currently trading at $0.7575. The market capitalization is $42.28M and the company ranks 4604 by market cap. These figures place PDSB among smaller-cap healthcare companies with a speculative profile.
The current price and market position come with notable volatility, as reflected in an annualized volatility figure that sits around 80. Forecasts for 2026 onward show a bullish path, with the average price rising to $5.19 by 2050 and an eventual return on investment (ROI) of 585.4%. The 2026 forecast average equals the current price, illustrating a long-term upside embedded in later years.
A major floor 37.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.2% away) — a key level to hold.
The nearest ceiling, 61.1% above — a clean break opens room to run.
A major ceiling 88.8% above — clearing it would confirm fresh momentum.
Key PDSB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PDSB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8134 | Sell | $0.8087 | Sell |
| MA 10 | $0.8463 | Sell | $0.8413 | Sell |
| MA 20 | $0.9049 | Sell | $0.8963 | Sell |
| MA 50 | $1.03 | Sell | $0.9601 | Sell |
| MA 100 | $0.9162 | Sell | $0.9566 | Sell |
| MA 200 | $0.907 | Sell | $1.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.30 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -139.00 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -15.13 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.89 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 8.78 | Buy |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.78 | Sell |
| ADX (14) | 18.30 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is neutral, with RSI14 at 30. The 50-day simple moving average (SMA50) is $1.03, and the 200-day simple moving average (SMA200) is $0.907. Near-term dynamics include a defined support at $0.774 and a resistance at $1.22.
The 30-day price range spans from $0.569 to $1.01, highlighting a relatively tight trading band around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.537 | $0.7575 | $1.03 | 0% | Neutral | |
| $0.5949 | $0.7906 | $1.13 | +4% | Neutral | |
| $0.6663 | $0.9285 | $1.40 | +23% | Bullish | |
| $0.7652 | $1.11 | $1.74 | +46% | Bullish | |
| $0.8805 | $1.32 | $2.15 | +75% | Bullish | |
| $0.9204 | $1.43 | $2.40 | +89% | Bullish | |
| $0.87 | $1.39 | $2.40 | +84% | Bullish | |
| $0.8251 | $1.36 | $2.41 | +80% | Bullish | |
| $0.7807 | $1.33 | $2.39 | +75% | Bullish | |
| $0.9493 | $1.66 | $3.05 | +119% | Bullish | |
| $1.05 | $2.10 | $4.20 | +177% | Bullish | |
| $2.34 | $5.19 | $11.71 | +585% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.537 | $0.7575 | $0.909 | +0.00% |
| August 2026 | $0.6423 | $0.7705 | $0.9579 | +1.72% |
| September 2026 | $0.6196 | $0.7517 | $0.9506 | -2.44% |
| October 2026 | $0.581 | $0.7118 | $0.9131 | -5.31% |
| November 2026 | $0.5979 | $0.7386 | $0.9589 | +3.77% |
| December 2026 | $0.6328 | $0.7879 | $1.03 | +6.67% |
Click any year to see its month-by-month PDSB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PDSB is projected to trade between $0.537 and $1.03, averaging $0.7575 — a potential gain of 0% from today's $0.7575. Price action looks broadly range-bound.
PDS Biotechnology Corporation's 2027 outlook centres on $0.7906, within a $0.5949 to $1.13 range. That is up +4% on the projected 2026 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, PDSB could reach as high as $1.40, with a base case around $0.9285 and support toward $0.6663 — roughly +23% from $0.7575. Momentum favours further upside here.
Expect PDSB to range from $0.7652 to $1.74 through 2029. The $1.11 average target implies a +46% move from current prices. That is up +20% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PDSB price prediction for 2030 points to an average of $1.32 (low $0.8805, high $2.15) — a potential gain of +75% on today's $0.7575. Momentum favours further upside here.
In 2031, PDSB is projected to trade between $0.9204 and $2.40, averaging $1.43 — a potential gain of +89% from today's $0.7575. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
PDS Biotechnology Corporation's 2032 outlook centres on $1.39, within a $0.87 to $2.40 range. That is -2% versus the projected 2031 average. That marks a +84% change versus current levels. Momentum favours further upside here.
By 2033, PDSB could reach as high as $2.41, with a base case around $1.36 and support toward $0.8251 — roughly +80% from $0.7575. Buyers look set to stay in control over this stretch.
Expect PDSB to range from $0.7807 to $2.39 through 2034. The $1.33 average target implies a +75% move from current prices. That is -3% versus the projected 2033 average. Momentum favours further upside here.
The PDSB price prediction for 2035 points to an average of $1.66 (low $0.9493, high $3.05) — a potential gain of +119% on today's $0.7575. Buyers look set to stay in control over this stretch.
In 2040, PDSB is projected to trade between $1.05 and $4.20, averaging $2.10 — a potential gain of +177% from today's $0.7575. That is up +27% on the projected 2035 average. Momentum favours further upside here.
PDS Biotechnology Corporation's 2050 outlook centres on $5.19, within a $2.34 to $11.71 range. That is up +147% on the projected 2040 average. That marks a +585% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PDSB today (≈ 1,320.132013 PDSB) could be worth
$6,854.22
+$5,854.22 (+585%) by 2050 · US Dollar
Based on the average projected PDSB price of $5.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PDSBwould be worth at today's price.
$1,000 invested in PDSB on Jul 10, 2025 (≈ 769.230797 PDSB) would be worth
$582.69
-$417.31 (-41.7%) today · 0.58× · US Dollar
Based on a PDSB entry price of $1.3 vs. today's $0.7575.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.853 | $888.04 | -11.2% |
| 1 month ago | $1.06 | $714.62 | -28.5% |
| 3 months ago | $1.08 | $701.39 | -29.9% |
| 6 months ago | $0.98 | $772.96 | -22.7% |
| 1 year ago | $1.3 | $582.69 | -41.7% |
| All time (5.0y) ago | $10.17 | $74.48 | -92.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PDSB forecast.
Our base-case forecast reaches $1.50 around 2035.
Implied market cap at $1.50: $83.72M
The year-by-year forecast shows a gradual, multi-year rise in average price and sizable ROI improvements later in the horizon. For 2026 the average price is $0.7575 with 0% ROI, followed by 2027 at $0.7906 (4.4% ROI) and 2028 at $0.9285 (22.6% ROI). By 2030 the average price reaches $1.32 with a 74.7% ROI, and 2031 shows $1.43 (88.8% ROI) while 2032 comes in at $1.39 (84.2% ROI).
The trajectory remains bullish through 2033 ($1.36, 79.9%), 2034 ($1.33, 75.2%), and 2035 ($1.66, 119%). In 2040 the average price is forecast at $2.10 with a 177.1% ROI, and by 2050 the average price could reach $5.19, representing a 585.4% ROI. These figures are estimates and reflect the potential for substantial upside while noting that outcomes are not guaranteed and depend on market and clinical development factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.32 with an ROI of 74.7%.
The forecast shows a bullish path with rising average prices and positive ROIs, including 74.7% in 2030 and 585.4% by 2050, but these are estimates and not guarantees.
Yes—the 2050 forecast shows an average price of $5.19 with an ROI of 585.4%.
Current price is $0.7575 and market capitalization is $42.28M.
Sentiment is NEUTRAL; RSI14 is 30. SMA50 is $1.03; SMA200 is $0.907. Support is at $0.774 and resistance at $1.22, with a 30-day range of $0.569 to $1.01.
PDS Biotechnology Corporation Community Discussion
0Share your PDS Biotechnology Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.